CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy

前列腺癌中的 CSF1 受体靶向逆转巨噬细胞介导的雄激素阻断疗法耐药性

阅读:10
作者:Jemima Escamilla, Shiruyeh Schokrpur, Connie Liu, Saul J Priceman, Diana Moughon, Ziyue Jiang, Frederic Pouliot, Clara Magyar, James L Sung, Jingying Xu, Gang Deng, Brian L West, Gideon Bollag, Yves Fradet, Louis Lacombe, Michael E Jung, Jiaoti Huang, Lily Wu

Abstract

Growing evidence suggests that tumor-associated macrophages (TAM) promote cancer progression and therapeutic resistance by enhancing angiogenesis, matrix-remodeling, and immunosuppression. In this study, prostate cancer under androgen blockade therapy (ABT) was investigated, demonstrating that TAMs contribute to prostate cancer disease recurrence through paracrine signaling processes. ABT induced the tumor cells to express macrophage colony-stimulating factor 1 (M-CSF1 or CSF1) and other cytokines that recruit and modulate macrophages, causing a significant increase in TAM infiltration. Inhibitors of CSF1 signaling through its receptor, CSF1R, were tested in combination with ABT, demonstrating that blockade of TAM influx in this setting disrupts tumor promotion and sustains a more durable therapeutic response compared with ABT alone.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。